Yangyang Song, Xinyu Ke and Polly Chen Leilei* Pages 1 - 26 ( 26 )
Breast cancer is one of the most lethal cancers in women worldwide, and the development of efficient treatments faces several challenges. Breast cancer is characterized by histological and functional heterogeneity in aspects such as tumorigenesis, metastasis and drug resistance. RNA therapy has emerged as highly attractive classes of drugs for the treatment and prevention of breast cancer. It might play remarkable regulatory roles in the treatment of targeted cells by either increasing or silencing expressions of specific proteins, and such features of RNA-based drugs cause high selectivity and low risk of off-target effect in breast cancer. RNA therapy exerts anti-proliferative and pro-apoptotic effects upon cell culture systems, animal models and in clinical trials in the most studies. In this mini review, we outline the classifications, mechanisms, advantages, and challenges of RNA therapy and highlight its application in breast cancer treatment. Additionally, we summarize the clinical trials of RNA-targeting therapies and the development of anti-tumor RNA drugs, and provide future directions for RNA therapeutics in breast cancer.
Breast cancer, RNA therapy, antisense oligonucleotides (ASOs), aptamers, RNA interference (RNAi), clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9).
Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599, Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599